Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. Co.'s pipeline is comprised of four programs being developed initially for the treatment of I&I indications. Co.'s two primary programs, APG777 and APG808, which Co. is initially developing for the treatment of AD and COPD, respectively. Moreover, Co. is evaluating APG777 in additional I&I indications, including asthma, areata, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and prurigo nodularis. The APGE average annual return since 2023 is shown above.
The Average Annual Return on the APGE average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether APGE average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the APGE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|